Global Scans · Leukemia · Weekly Summary

• Intellia plans to start clinical studies for NTLA-5001 in acute myeloid leukemia shortly. Entrepreneur Europe
• The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia. The Scientist
• The changes associated with immune system ageing observed in men are globally less extensive, but an increase in certain blood cells presenting pre-leukemia alterations was observed, a fact that could explain why some blood cancers are more frequent in older men. Fight Aging!
• HMC-1 cells containing common KIT variants, isolated from a patient with mast cell leukemia, remain one of the most frequent preclinical models to test the efficacy of drugs targeting oncogenic KIT activity and to predict signaling pathways and behaviour of neoplastic mast cells. Frontiers
• A new drug approval by the Food and Drug Administration (FDA) is expected to help address a critical need for children with leukemia who develop an allergy to a key component of their treatment. National Cancer Institute
• Moving forward, Wugen will start a global, multicenter study for WU-NK-101 and file an IND for its CAR-T program in T-cell leukemia and lymphoma later in 2021. FierceBiotech
• A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been developed in alignment with the US Food and Drug Administration and the first patient visit is expected in early 2021. Benzinga
• Beam plans two IND applications in 2022 - one for its second SCD candidate BEAM-102, and the other for BEAM-201, a treatment for relapsed / refractory T cell acute lymphoblastic leukemia / T cell lymphoblastic lymphoma. GEN - Genetic Engineering and Biotechnology News
• The CDC indicated that children who were exposed to the contaminated Camp Lejeune water during fetal gestation had an increased risk of developing childhood cancers like leukemia. Lawsuit Information Center Blog
• In the USA the expected number of new cases per year for leukemia is ~60,000, and for lymphoma is ~90,000. Frontiers
• BEAM-201, an experimental treatment for leukemia and lymphoma, was expected to follow in 2022 along with a second sickle cell drug called BEAM-102. BioPharma Dive
• Enforced expression of BCR-ABL, the unique oncogenic driver of Chronic Myelogeneous Leukemia, in Embryonic Stem Cells - derived hematopoietic cells is sufficient to confer long-term in vivo repopulating potential. bioRxiv

Last updated: 21 June 2026